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Exon skipping is capable of correcting frameshift and
nonsense mutations in Duchenne muscular dystro-
phy. Phase 2 clinical trials in the United Kingdom and
the Netherlands have reported induction of dystro-
phin expression in muscle of Duchenne muscular
dystrophy patients by systemic administration of
both phosphorodiamidate morpholino oligomers
(PMO) and 2=-O-methyl phosphorothioate. Peptide-
conjugated phosphorodiamidate morpholino offers
significantly higher efficiency than phosphorodiami-
date morpholino, with the ability to induce near-nor-
mal levels of dystrophin, and restores function in
both skeletal and cardiac muscle. We examined 1-year
systemic efficacy of peptide-conjugated phosphoro-
diamidate morpholino targeting exon 23 in dystro-
phic mdxmice. The LD50 of peptide-conjugated phos-
phorodiamidate morpholino was determined to be
approximately 85 mg/kg. The half-life of dystrophin
expression was approximately 2 months in skeletal
muscle, but shorter in cardiac muscle. Biweekly injec-
tion of 6 mg/kg peptide-conjugated phosphorodiami-
date morpholino produced >20% dystrophin expres-
sion in all skeletal muscles and <5% in cardiac
muscle, with improvement in muscle function and
pathology and reduction in levels of serum creatine
kinase. Monthly injections of 30 mg/kg peptide-con-
jugated phosphorodiamidate morpholino restored
dystrophin to >50% normal levels in skeletal muscle,
and 15% in cardiac muscle. This was associated with
392greatly reduced serum creatine kinase levels, near-
normal histology, and functional improvement of skel-
etal muscle. Our results demonstrate for the first time
that regular 1-year administration of peptide-conjugated
phosphorodiamidate morpholino can be safely applied
to achieve significant therapeutic effects in an animal
model. (Am J Pathol 2012, 181:392–400; http://dx.doi.org/
10.1016/j.ajpath.2012.04.006)
Duchenne muscular dystrophy (DMD) is the most com-
mon and lethal muscle disorder with onset in early child-
hood, and no effective treatment is available. DMD is
caused mainly by nonsense and frameshift mutations of
the dystrophin gene (DMD), leading to the lack of func-
tional dystrophin protein in muscle. Becker muscular
dystrophy (BMD), an allelic form of DMD, is caused by
mutations that typically create shortened but in-frame
transcripts with production of partially functional dystro-
phin; in BMD, patients have variable or no symptoms.1–3
Antisense oligomer-mediated exon skipping has been
demonstrated to have high potential for open reading
frame restoration of the dystrophin gene and for induction
of BMD-like functional dystrophin; significant progress in
exon skipping for DMD has been made.4–28 Therapeutic
potential of exon skipping was first demonstrated in dys-
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injection.12 Since then, systemic efficacy with improve-
ment in muscle function has been demonstrated in dys-
trophic mouse and dog with phosphorodiamidate mor-
pholino oligomers (PMOs).14,18 Phase 1 clinical trials
targeting human dystrophin exon 51 demonstrated
dystrophin expression in muscle injected with specific
antisense oligonucleotide (AO) of PMO and 2=-O-
methyl phosphorothioate (2OMePS).19,20 In a phase 2a
trial, systemic administration of the antisense drug
PRO051 (2OMePS) was assessed in DMD patients,
with a weekly subcutaneous injection regimen for 17
weeks; exon 51 skipping and increased dystrophin
expression were reported in a dose-related manner in
all cohorts at doses of 0.5, 2, 4, and 6 mg/kg.21 More
recently, a phase 2 clinical trial with repeated weekly
intravenous injections of PMO targeting the same hu-
man dystrophin exon 51 reported encouraging prelim-
inary results. Up to 20 mg/kg per injection of AVI-4658
showed a dose-dependent restoration of dystrophin
expression.22 At the doses tested, both compounds
appeared to be well tolerated, although functional con-
sequences and cumulative effects of long-term treat-
ment remain to be demonstrated.
Use of the compounds PMO and 2OMePS as currently
in clinical trials is limited by their low efficiency and high
variability in exon skipping and dystrophin induction in all
muscles, as revealed from studies in both animal models
and the clinical trials. One special concern is the very low
efficiency of exon skipping in cardiac muscle, which in
boys with DMD is severely affected by the lack of dys-
trophin expression. Results from animal model studies
suggest that a detectable dystrophin induction in cardiac
muscle will require biweekly injections of PMO at 60
mg/kg.23 This has led to the use of cationic peptides and
other polymers to improve the efficiency of PMO deliv-
ery.15,16,24–28 PMOs conjugated with an arginine-rich pep-
tide (PPMO) were able to restore dystrophin expression to
near-normal levels in bodywide skeletal muscle and to ap-
proximately 50% in cardiac muscle at a dose of 30 mg/kg
by single injection. Such high levels of dystrophin expres-
sion significantly improved function of both skeletal and
cardiac dystrophic muscle.15 However, it is well docu-
mented that the use of positively charged peptides and
polymers increases toxicity considerably.15,16,26–28 This to-
gether with the requirement of lifelong AO drug administra-
tion for treating DMD necessitates investigation of these
modified PMOs for their long-term applicability and efficacy
in relevant animal models in vivo.
In the present study, we investigated the acute toxicity
and dose-related 1-year efficacy of PPMO treatment target-
ing mouse dystrophin exon 23 systemically in dystrophic
mdx mice. Our results show that PPMO has a high level of
acute toxicity (the LD50 is approximately 85 mg/kg). How-
ever, the effective dose for inducing 20% dystrophin in
skeletal muscle and 5% dystrophin in cardiac muscle re-
quires only 6 mg/kg biweekly injections with no obvious
acute or chronic adverse effects were detected. PPMO
could therefore be an effective candidate compound as AO
drugs for long-term treatment of DMD.Materials and Methods
Animals, Oligonucleotides, and in Vivo Delivery
Methods
In each treatment group, 10 mdx or C57BL/6 mice aged
4 to 5 weeks were used. Experiments were approved by
the Institutional Animal Care and Use Committee of the
Carolinas Medical Center. The phosphorodiamidate mor-
pholino oligomer (07-18) (5=-GGCCAAACCTCGGC-
TTACCTGAAAT-3=) was used against the boundary se-
quences of exon and intron 23 of the dystrophin gene
and was conjugated to the peptide (RXRRBR)2XB (where
R is arginine, X is 6-amino-hexanoic acid, and B is -al-
anine) through a noncleavage amide linker to form a
peptide-PMO conjugate (PPMO) (AVI BioPharma, Both-
ell, WA). For intravenous administration by retro-orbital
injection, the PPMO was used in 100 L saline; control
mdx mice were injected with 100 L saline only. Mice
were sacrificed at various time points, and muscles were
snap-frozen in liquid nitrogen–cooled isopentane and
stored at 80°C.
Antibodies and Immunohistochemistry
Sections (6 m thick) were cut from at least two thirds of
the muscle length of tibialis anterior (TA), quadriceps,
biceps, and gastrocnemius muscles at 100-m spacing
and from at least six levels from all other muscles (includ-
ing cardiac, diaphragm, intercostal, and abdominal mus-
cle) at 100-m spacing. The intervening muscle sections
were collected for Western blot and RT-PCR analysis.
The serial sections were stained with rabbit polyclonal
antibody P7 against dystrophin. The primary antibody
was detected by goat-anti-rabbit IgG Alexa Fluor 594
(Invitrogen-Life Technologies, Carlsbad, CA). Sections
were also stained with H&E for histological assessment.
Protein Extraction and Western Blot
The collected sections were ground into powder and
lysed with 200 L protein extraction buffer, as described
previously.15,16 The protein concentration was quantified
by a protein assay kit (Bio-Rad Laboratories, Hercules,
CA). Proteins were loaded onto a 4% to 15% Tris-HCL
gradient gel. Samples were electrophoresed overnight at
10 mA at 4°C and blotted onto nitrocellulose membrane
overnight at 50 V. The membrane was then washed and
blocked with 5% nonfat milk and probed overnight with
monoclonal antibody against the dystrophin rod domain
(NCL-DYS1; Vector Laboratories, Burlingame, CA). Anti-
body against kidney injury molecule-1 (KIM-1; also
known as hepatitis A virus cellular receptor 1 homolog, or
HAVcr-1) (R&D Systems, Minneapolis, MN) was used for
detecting expression of KIM-1 in the kidney. The bound
primary antibody was detected by horseradish peroxi-
dase-conjugated goat anti-mouse IgG for dystrophin
(Santa Cruz Biotechnology, Santa Cruz, CA) or horserad-
ish peroxidase-conjugated donkey anti-goat IgG for
KIM-1 (Millipore, Billerica, MA) and a Western blotting
enzymatic chemiluminescence analysis system (Perkin
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from the AO-treated muscle was measured and com-
pared with that from normal muscle of C57BL/6 mice
(ImageJ software version 1.42; NIH, Bethesda, MD).
RNA Extraction and RT-PCR
The collected sections were homogenized in TRIzol (In-
vitrogen) in an Ultra-Turrax homogenizer (Janke & Kun-
kel, Staufen, Germany). Total RNA was then extracted,
and 100 ng of RNA template was used for a 50-L RT-
PCR with a master mix from USB (Cleveland, OH). The
primer sequences for the RT-PCR were Ex20Fo 5=-
AGAATTCTGCCAATTGCTGAG-3= and Ex26Ro 5=-TCTT-
CAGCTTGTGTCATCC-3= for amplification of mRNA from
exons 20 to 26. In total, 40 cycles were performed for the
RT-PCR. Bands with the expected size for the transcript
with deletion of exon 23 were extracted and sequenced.
The intensity of the bands was measured with ImageJ
software; the percentage of exon skipping was calcu-
lated with the intensity of the two bands representing
exon 23 unskipped and skipped as 100%.
Grip Strength Test
Grip strength was assessed using a grip strength meter
consisting of horizontal forelimb mesh and an angled
hindlimb mesh (Columbus Instruments, Columbus OH).
Five successful hindlimb and forelimb strength measure-
ments within 2 minutes were recorded, and data were
normalized to body weight and expressed as kilogram
force.
Measurement of Serum Creatine Kinase and
Other Components
Mouse blood was taken immediately after cervical dislo-
cation and centrifuged at 200  g for 3 minutes. Serum
was separated and stored at 80°C. The level of serum
components was determined by Charles Riverside Lab-
oratories International (Wilmington, MA).
Results
LD50 of PPMO in mdx Mice
Our research group previously showed that 30 mg/kg
PPMO was able to induce almost normal levels of dys-
trophin expression in bodywide muscle ofmdxmice with-
out clearly observable acute or chronic toxicity, even
after six rounds of biweekly intravenous injection.15
Nonetheless, acute toxicity remains a serious concern,
especially because repeated, lifelong administration is
required for treating DMD. We therefore first tested the
same PPMO targeting mdx mouse exon 23 by dose es-
calation from 6 mg/kg, to determine the LD50. All surviv-
ing mice were sacrificed 2 weeks after injection. In ac-
cord with previous report, all mice injected with 6 mg/kg
PPMO survived without any observable difference from
saline-injected control mice.15 All mice receiving 30mg/kg PPMO also survived without loss of body weight;
the only observable change was reduced activity during
the first 2 hours after injection in 3 of the 10 mice in this
group. When the dose of PPMO was increased to 60
mg/kg, however, all mice showed reduced activity after
recovery from anesthesia. Of the 10 treated mdx mice, 2
died within 5 minutes after the intravenous injection, and
1 died within 24 hours. Further increase in dose to 90
mg/kg PPMO resulted in the death of 5 out of 10 mice
within 2 days after injection, and with increase to 120
mg/kg, 8 out of 10 mice died within 2 days (Figure 1). The
LD50 of PPMO in mdx mice was thus determined to be
approximately 85 mg/kg.
Half-Life of Dystrophin Expression after Single
Intravenous Administration of 30 mg/kg PPMO
Our previous study demonstrated that a single intrave-
nous injection of 30 mg/kg PPMO induced 100% and
50% of normal levels of dystrophin expression in body-
wide skeletal muscle and cardiac muscle, respectively.15
To assess the possible half-life of dystrophin expression,
we applied the same dose of 30 mg/kg of the PPMO
targeting exon 23 by single intravenous injection intomdx
mice and examined the levels of dystrophin expression at
a series of time points (2 days, 2 weeks, and 1, 1.5, 2.5,
4, and 5 months after the injection) (Figure 2A). At 2 days
after intravenous injection, nearly 100% efficiency in exon
23 skipping was detected by RT-PCR (Figure 2B). Dys-
trophin protein was detected by Western blot at approx-
imately 20% of normal levels (Figure 2, C and D), and
50% dystrophin-positive fibers were detected by immu-
nohistochemistry in all skeletal muscles examined (Figure
2A). In cardiac muscle, 40% efficiency in exon 23 skip-
ping was detected; however, dystrophin protein was not
convincingly detected by Western blot (Figure 2). By 2
weeks, dystrophin expression in skeletal muscle was de-
tected in nearly 100% of muscle fibers, with the protein
reaching 80% of normal levels.15 Similar levels of dys-
trophin protein and percentage of dystrophin-positive fi-
bers were maintained up to 2.5 months after the single
injection; however, exon-skipping efficiency was signifi-
cantly reduced, down to approximately 50% at 2.5
months after the injection. The levels of dystrophin de-
creased to 30% of normal levels at 4 months after the
Figure 1. LD50 of PPMO in mdx mice. No death was recorded in the groups
treated with 6 mg/kg PPMO or 30 mg/kg PPMO, but 3, 5, and 8 mice died in
the groups treated at doses of 60, 90, and 120 mg/kg PPMO, respectively.
Probit analysis was used to calculate the LD50 from mortality rates. n  10
mice per group.injection and to 10% at 5 months. In cardiac muscle,
blot (C
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peaked at 1 month after the injection, reaching approxi-
mately 70% of normal levels, and then decreased to
50% at 1.5 months and to25% at 2.5 months after the
injection. No dystrophin was detected at 4 and 5 months
in cardiac muscle by either immunohistochemistry or
Western blot (Figure 2, A, C, and D). The data thus
indicate that PPMO induces dystrophin expression ap-
proximately two times more efficiently in skeletal muscle
than in cardiac muscle.
Figure 2. Half-life of dystrophin expression after a single intravenous a
immunohistochemistry with rabbit polyclonal antibody P7 against dystrophin
B: Detection of exon 23 skipping in muscle by RT-PCR. The first lane is a size
was used as loading control. Muscles were examined at various time points, f
PPMO. Horizontal axis labels apply to lanes for both RT-PCR (B) and Western
Cont-TA, TA muscle from control mdx mouse.The half-life of dystrophin expression was also longer
in skeletal muscle than in cardiac muscle. Consistent with
our previous results, expression of high levels of dystro-
phin after a single 30 mg/kg PPMO treatment improved
muscle pathology of the mdx mice (Figure 3A). The per-
centage of muscle fibers without central nucleation in-
creased time-dependently from 20% at 1 month after the
single-dose treatment to 40% at 4 months, but then de-
creased to 30% by 5 months in most skeletal muscles,
except diaphragm (Figure 3B). No areas of muscle de-
ration of 30 mg/kg PPMO in mdx mice. A: Detection of dystrophin by
API was used as a nuclear counterstain (blue) (original magnification,200).
C:Western blot shows levels of dystrophin expression in muscle. D: -Actin
ays to 5 months, in mdx mice after a single intravenous injection of 30 mg/kg
and D). Scale bar 20 m. C57-TA, TA muscle from normal C57BL/6 mouse;
Figure 3. Examination of pathology, serum, and
muscle fiber central nucleation in mdx mice at
different time points after a single intravenous ad-
ministration of 30 mg/kg PPMO. A: Histology
(H&E staining) of diaphragm, TA, and quadriceps
muscle at four time points (1 to 5 months) after
PPMO treatment (original magnification,200). B:
Percentages of muscle fibers without central nu-
cleation at five different time points (1 to 5
months). C: Serum enzyme levels. Significant re-
ductions in CK levels were observed at different
points in mdx mice treated with 30 mg/kg PPMO,
comparedwith controlmdxmice. *P 0.05 versus
C57BL/6 mice; †P 0.05 versus controlmdxmice,
two-tailed t-test. n  10. ALP, alkaline phospha-
tase; ALT, alanine transaminase; Bili, bilirubin;
GGT, -glutamyltransferase.dminist
(red). D
marker.
rom 2 d
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observed in any of the skeletal muscles examined (in-
cluding TA, quadriceps, biceps, and gastrocnemius) be-
tween 2 weeks and 5 months after treatment. In dia-
phragm, the percentage of fibers without central
nucleation also increased at first, reaching their highest
level by 2.5 months, but then decreased again by 4
months (Figure 3B). The increase of fibers with central
nucleation was associated with an increase in areas with
degenerating fibers and foci of mononucleocyte infiltra-
tion. Thus, a single dose of PPMO treatment provides a
shorter period of protection from degeneration for dia-
phragm than for other skeletal muscles. Serum creatine
kinase (CK) levels were reduced significantly and re-
mained at similar low levels from 1 month to 5 months
after the injection (Figure 3C).
Biweekly Administration of 1.5 mg/kg PPMO for
1 Year Produces Limited Dystrophin Induction
and Improvement in Muscle Function
The high efficiency of PPMO for dystrophin induction but
relatively low LD50 call for a low-dose regimen for treating
DMD. We hypothesized that repeated low-dose PPMO
administration might be sufficient to induce functionally
meaningful dystrophin expression. The mdx mice were
therefore treated with PPMO at a dose of 1.5 mg/kg with
biweekly intravenous injection for 1 year. Immunohisto-
chemistry for dystrophin expression 2 weeks after the
final injection showed 20% of muscle fibers expressing
detectable dystrophin, most of them with weak signals in
bodywide skeletal muscle (Figure 4A). The amount of
dystrophin protein detected by Western blot ranged from
barely detectable to 5% of normal level in any skeletal
muscle. This amount of protein was similar to that de-
tected in muscle after a single intravenous injection of 1.5
mg/kg PPMO, suggesting no significant accumulation of
efficiency after 1 year of treatment (Figure 4, D–F). No
clear difference in pathology was observed, including
percentage of centrally nucleated fibers and variation in
fiber size (Figure 4A). Consistently, no significant im-
provement was observed in CK levels and skeletal mus-
cle function measured by grip force generation of the
treated group (Figure 5D). Neither dystrophin expression
nor exon 23 skipping was detected in cardiac muscle by
immunohistochemistry, Western blot, and RT-PCR (Fig-
ure 4). Body weight, serum enzyme tests, and histologi-
cal examination of lung, kidney, and liver showed no
clear difference between PPMO-treated and control mdx
mice (Figure 5, A–C).
Administration of 6 mg/kg PPMO Induces
High Levels of Dystrophin Expression with
Improvement of Muscle Pathology and Function
We then examined the long-term effect of a higher dose
of PPMO (6 mg/kg) in regular biweekly intravenous injec-
tions. After 1 year of treatment, skeletal muscles exhibited
dystrophin-positive fibers ranging from 60% up to 90%.
Considerable variation in levels of dystrophin stainingwas also clearly detected in all muscles (Figure 4A).
RT-PCR showed 15% to 50% exon 23 skipping in skeletal
muscle (Figure 4B). The levels of dystrophin expression
detected by Western blot ranged from 20% to 50% of
normal levels (Figure 4, D and F). Histologically, treated
skeletal muscle exhibited clearly detectable improve-
ment, with reduced central nucleation and a more homo-
geneous population of fibers in size (Figure 5A); however,
sporadic foci of degeneration and regeneration and
monocyte infiltration remained in all muscles. Significant
improvement was also detected in muscle function with
grip force generation (Figure 5C). This finding was sup-
ported by a significant reduction in CK levels, compared
with control mdx mice, although the CK levels were still
higher than those of normal C57BL/6 mice (Figure 5D).
Expression of dystrophin in cardiac muscle was clearly
detectable in a proportion of fibers with weak and dis-
continuous membrane staining by immunohistochemis-
try, but was5% of normal levels by Western blot (Figure
4, D–F). As described above for the group treated with
1.5 mg/kg PPMO, 6 mg/kg PPMO did not show clear
differences in body weight, serum enzyme tests, or his-
tological examination of lung, kidney, and liver, com-
pared with control mdx mice (Figure 5). These results
suggest that the effect of PPMO treatment at this dose
can achieve measurable therapeutic outcome in skeletal
muscle without detectable toxicity.
30 mg/kg PPMO Monthly Treatment Restores
Near-Normal Levels of Dystrophin with
Improvement of Muscle Pathology and Function
With the demonstration that the half-life of dystrophin
induced by a single intravenous injection of 30 mg/kg
PPMO is approximately 2 months, we designed a 1-year
treatment of 30 mg/kg PPMO with monthly intravenous
injection. The 1-year treatment was able to achieve dys-
trophin expression in nearly 100% of muscle fibers in
bodywide skeletal muscle. Western blot detected 50%
of normal levels of dystrophin protein in most skeletal
muscles, although lower levels (as low as 25%) were also
detected (Figure 4, E and G). Muscle pathology was
clearly improved, with almost no degenerating fibers in
any skeletal muscle examined (Figure 5A). The fibers
within the same muscle became highly uniform, with no
clear inflammatory cell infiltrations. Foci of degeneration
and regeneration and monocyte infiltration, which re-
mained in most muscles after lower-dose treatment, were
absent in diaphragm. Consistently, CK levels were sig-
nificantly reduced, compared with control mdx mice (Fig-
ure 5D). Muscle function as measured by grip force gen-
eration was significantly improved (Figure 5C). The levels
of dystrophin expression in cardiac muscle were consid-
erably lower than those detected in skeletal muscle, but
was observed in 50% cardiac muscle fibers, and the
amount of dystrophin protein reached 15% in cardiac
muscle of all the PPMO-treated mice (Figure 4).
The mice under this dosage treatment showed no sign
of abnormal body weight change when compared with
the controlmdxmice. No pathological change of the liver,
els app
dx mou
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AJP August 2012, Vol. 181, No. 2kidney, and lung was observed under H&E staining (Fig-
ure 5A). This finding was supported by serum tests,
which showed normal levels of creatinine, total bilirubin,
alkaline phosphatase, -glutamyltransferase, and blood
urea nitrogen (Figure 5D). We also examined the levels of
KIM-1 expression in the kidney of the PPMO-treated mice
byWestern blot. All kidneys from both the 1.5 mg/kg and 30
mg/kg PPMO-treatedmice showed barely detectable levels
Figure 4. Restoration of dystrophin expression in mdx mice after 1 year of
by immunohistochemistry with rabbit polyclonal antibody P7 against dystro
200). B and C: Detection of exon 23 skipping in muscle by RT-PCR. The fir
in muscle. F and G: -Actin was used as loading control. Horizontal axis lab
muscle from normal C57BL/6 mouse; Cont-TA, TA muscle from untreated mof KIM-1 expression, similar to those from untreated mdxand C57BL/6 control mice (see Supplemental Figure S1 at
http://ajp.amjpathol.org).
Discussion
Cationic peptides, also referred as cell-penetrating pep-
tides, have been widely used for gene and oligonucleo-
ous treatment with 1.5, 6, and 30 mg/kg PPMO. A: Detection of dystrophin
d). DAPI was used as a nuclear counterstain (blue) (original magnification,
a size marker. D and E:Western blots show levels of dystrophin expression
ly to lanes for both RT-PCR (B and C) and Western blot (D–G). C57-TA, TA
se.intraven
phin (re
st lane istide delivery. Successful applications of such peptides in
398 Wu et al
AJP August 2012, Vol. 181, No. 2vivo, however, have been limited. One major limitation is
toxicity.15,24–28 Data from previous studies in mouse
models showed that doses inducing near-normal levels
of dystrophin expression by a PPMO containing the cat-
ionic peptide (RXRRBR)2XB sequence did not cause ob-
vious short-term toxicity.15 The PPMO showed no toxic
effect either at 20 mg/kg for six weekly injections in wild-
type mice or at 30 mg/kg for 3 months of biweekly injec-
tions in mdx mice.15,27 At these doses, adverse effects
were detected in some mice, including an acute lethargy
lasting up to a few hours after systemic injection. There
was no clear toxicity in the kidney and liver, as assessed
both by histology and by the levels of serum enzymes at
the end of the PPMO intervention. Nonetheless, toxicity of
PPMO has been reported as weight loss and tubular
degeneration in kidney.26–28 Results from the present
study confirmed that PPMO at 30 mg/kg by monthly in-
jections caused only mild lethargy in some mice imme-
diately after the systemic injection. However, further in-
crease of the dose to 60 mg/kg led to death in some ofthe treated mice within 48 hours, and the remaining mice
showed clear lethargy within 2 to 4 days. When the single
dose was 120 mg/kg, 80% of the animals died. These
findings suggest that the LD50 of PPMO is approximately
85 mg/kg. All of the data together support the notion
raised by Moultons27 that there seems to be a dose
threshold for the toxicity of PPMO: below the threshold,
acute toxicity cannot be clearly observed; above it, the
severity of toxicity increases rapidly in a dose-dependent
manner. The severity of toxicity is also suggested to be
dependent on dose frequency.27
One specific concern for PPMO is the potential chronic
toxicity to kidney. The same peptide-conjugated PMO
(AVI-5038) as used in the present study, but targeting
human exon 50, was reported to cause tubular degener-
ation (although mild) in the kidneys of monkeys after four
weekly injections of only 9 mg/kg.27 Elevated blood urea
nitrogen levels were also reported in the rat treated with a
similar peptide-conjugated PPMO.28 In this study, how-
Figure 5. Examination of pathology,
serum, and skeletal muscle function in
mdx mice after 1 year of treatment with
1.5, 6, and 30 mg/kg PPMO. A: Histol-
ogy (H&E staining) of TA, quadriceps,
diaphragm, kidney, and liver from nor-
mal C57BL/6 mice (C57), control mdx
mice (Control), and mdx mice (original
magnification, 200). B: Percentage of
muscle fibers without central nucleation.
C: Grip strength measurement. Signifi-
cant improvement was observed in the
mice after treatment with 6 mg/kg and
30 mg/kg PPMO. D: Serum enzyme lev-
els. Significant reductions in CK levels
were observed in mdx mice treated with
6 mg/kg and 30 mg/kg PPMO, com-
pared with control mdx mice. *P  0.05
versus C57BL/6 mice; †P  0.05 versus
control mdx mice, two-tailed t-test. n 
10. ALP, alkaline phosphatase; ALT, ala-
nine transaminase; Bili, bilirubin; GGT,
-glutamyltransferase; KGF, kilogram
force.ever, no clear kidney damage was indicated by histology
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trogen and detection of KIM-1. Although the reasons for
such discrepancies are not understood, two factors are
most likely involved. In the present study, the kidney was
examined 2 weeks after the last treatment, whereas in the
other studies the serum and kidney were examined within
1 week after PPMO treatment. Our longer interval might
have provided sufficient time for some kidney damage to
recover. Perhaps more importantly, different species may
respond to the drug differently, given that the other stud-
ies used three different animals. Nevertheless, the low
LD50 of the PPMO established in the present study and
the possibly greater sensitivity of higher mammals (in-
cluding humans) to the peptide raise serious safety con-
cern for clinical use of the PPMO, especially for the re-
peated injections that are essential to maintain
therapeutic levels of dystrophin in bodywide muscle in
DMD patients. Thus, further studies in higher mammals
with different dose regimes are essential before transla-
tion to the clinic, and the biggest challenge for PPMO as
antisense drug chemistry is to determine safe and effec-
tive doses.27
A threshold effect may also apply to the efficiency of
exon skipping with dosing of PPMO. AVI-5038 targeted to
skip human dystrophin exon 50 is currently in preclinical
development for DMD patients. Initial efficacy of the
PPMO in four healthy cynomolgus monkeys showed that
weekly intravenous injection of 9 mg/kg for 4 weeks in-
duced an average of 40%, 25%, and 2% exon-skipping
effect in diaphragm, quadriceps, and cardiac muscle,
respectively.27 On the same schedule but at a lower
dose (3 mg/kg), however, little exon-skipping product
was detected. A similar trend was observed in the
present study. Nearly all skeletal muscles expressed
20% levels of dystrophin protein, as assessed by
Western blot, and 60% fibers clearly stained for dys-
trophin by immunohistochemistry, with 5% in cardiac
muscle in mdx mice treated with 6 mg/kg PPMO. With
the 1.5 mg/kg PPMO treatment, however, exon skip-
ping was barely detectable by RT-PCR, and dystrophin
protein was detected in 20% of muscle fibers. Simi-
larly, dystrophin protein was barely detected in most
muscles, although 5% expression was detected in
some skeletal muscles by Western blot. No dystrophin
was detected in cardiac muscle. These results indicate
a nonlinear relationship between the dose and the ef-
ficiency of dystrophin induction with systemically de-
livered PPMO. In clinical application, therefore, a
threshold dose of PPMO may be required to achieve
significant levels of dystrophin production and conse-
quent functional improvement for DMD patients.
Results from the present study with three different dos-
ing regimes provided a baseline for our assessment of a
possible therapeutic window for PPMO treatment of
DMD. Monthly treatment at a dose of 30 mg/kg was
effective for maintaining near-normal levels of dystrophin
in all muscles, with highly significant rescue effect on
muscle pathology and function. Similar to what we ob-
served previously in the study of short-term effects with
biweekly PPMO administration,15 this dosing regimen ap-
peared to be safe for long-term administration withoutobservable chronic toxicity, as indicated by normal levels
of serum enzymes in liver and kidney. No pathology was
revealed by histology of all skeletal muscles, cardiac
muscle, liver, kidney, and lung, which was further sup-
ported by the normal behavior and life span of the treated
mice. Nonetheless, despite the high efficacy associated
with only mild lethargy immediately after the injection, this
monthly dose is apparently too close to the LD50 and
must be tested in higher mammals before being consid-
ered for clinical application.
At the dose of 6 mg/kg with a biweekly injection, PPMO
induced 20% dystrophin in all skeletal muscles. De-
spite clear variation in the distribution and levels of dys-
trophin expression between and within muscles, func-
tional improvement was evident by the demonstration of
serum CK levels and histopathology. Also, and impor-
tantly, this dose induced a significant amount (5%) of
dystrophin in cardiac muscle. This dose of PPMO is at
least 10-fold less than the LD50 and therefore could be
considered as having potential for long-term clinical
treatment of DMD.
Efficacy of antisense therapy for individual DMD pa-
tients depends on many other factors, especially the
efficiency of individual antisense oligomers and the
functionality of the truncated dystrophin created by
exon skipping. AOs targeting individual human dystro-
phin exons need to be identified. Selection of AO tar-
geting human and mouse dystrophin exons involves
different cells and animal models. Thus, care must be
exercised in extrapolating the effective dose obtained
in the present study to clinical applications of PPMOs
targeting human dystrophin exons. A more accurate
estimation in exon-skipping efficiency of individual
PMOs may become possible when efficiency from the
first clinical trials of a PMO drug become available.
This may be achieved by comparing new AO drugs
with a PMO of known exon-skipping efficiency side by
side in the same testing system or systems, preferably
in both cell culture and in in vivo animal model system-
ically.
The functionality of the truncated dystrophin protein
created by skipping of a different exon must also be
taken into account for establishing relevant therapeutic
dose. Unfortunately, functionality of most of those trun-
cated dystrophins remains to be determined. Such inves-
tigations are required if the therapy is to apply effectively
to defined DMD populations; perhaps more important,
such investigations are required in some cases to deter-
mine the choice of the exon or exons to skip for highest
functionality of the restored dystrophin.
In summary, PPMOs as antisense drugs have demon-
strated the highest efficacy for long-term treatment of
DMD. The LD50 of the PPMO in the present study was
approximately 85 mg/kg, significantly lower than that of
PMO without toxicity at doses of 3 g/kg in mdx mice.
Nonetheless, the low LD50 may be mitigated by the high
efficiency of the PPMO, permitting the safe use of lower
doses that are still capable of achieving significant long-
term therapeutic effect.
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